The
effectiveness of Antimic® (3-(trimethoxysilyl)-propyl, cocodimethylammonium
chloride) against different nosocomial pathogens was evaluated. Despite the
fact that Antimic® biocide is a recommended compound for disinfecting areas,
there is no published data about the antibacterial activity of this formulation
against nosocomial pathogens (Acinetobacter baumanii, methicillin-resistant
Staphylococcus aureus, vancomycin-resistant Enterococcus faecium). The minimum
inhibitory/minimum bactericidal effective concentrations for test bacteria were
determined. The bactericidal activity of determined dosages was evaluated using
the culture-based quantitative suspension test (British Standards BS EN 1276)
for 1 and 5-minute contact period, under clean and dirty conditions.
Antibacterial activity was also confirmed by fluorescence staining. The biocide
was found to be effective at 25 and 50 mg/L concentrations at contact times of
1 and 5 minute, with ≥ 5 log reduction in all bacteria. According to fluorescent
microscopic examinations similar bacteria reduction was determined as ≥ 5 log
reduction. The results indicated that Antimic® compound meets the requirements
of EN 1276 against the tested bacteria. Moreover, Antimic® biocide provide an
advantage by not promoting the viable but non culturable state in the tested
bacteria and removing the tested bacteria successfully. The results showed that
the execution of different microbiological growth and/or antibacterial activity
monitoring tests, simultaneously, provide information about the optimum
concentration and contact time of a biocide.
Journal Section | Research Articles |
---|---|
Authors | |
Publication Date | December 27, 2017 |
Submission Date | December 12, 2017 |
Published in Issue | Year 2017 Volume: 76 Issue: 2 |